Jubilant Therapeutics appoints Dr. Robert Glassman as a member of the Board of Directors

Bedminster, New Jersey (ots/PRNewswire) Jubilant Therapeutics Inc., a biopharmaceutical company developing small molecule modulators for unmet medical needs in oncology and autoimmune diseases, today announced the inclusion of Dr. Robert Glassman announced to the company’s board of directors. Dr. Glassman will serve as an independent non-executive director effective February 1, 2021.

“Rob’s experience and insight will add a new dimension to the company as we pursue our growth strategy and we warmly welcome him to our board of directors,” said Hari Bhartia, Chairman of Jubilant Therapeutics.

“Rob is a recognized leader in the biopharmaceutical industry and his oncology background and financial acumen will be invaluable in realizing our strategic goals,” said Syed Kazmi, President and Chief Executive Officer of Jubilant Therapeutics.

Dr. Glassman is a public equity venture partner at OrbiMed Advisors. He has more than 17 years of experience in investment banking, most recently as Managing Director and Vice Chairman in the Global Investment Banking Group of Credit Suisse since 2015. Before joining Credit Suisse, Dr. Glassman worked for Merrill Lynch Global Private Equity where he managed a very successful healthcare portfolio. Prior to that, he served at McKinsey & Company as a consultant to a variety of healthcare clients in the United States and Europe. He was previously a certified hematologist and oncologist and remains as a clinical assistant professor of medicine on the faculty of Weill Cornell. Dr. Glassman received his AB magna cum laude from Harvard College and an MD from Harvard Medical School. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania and his fellowship in hematology and oncology at Weill Cornell. He was a researcher at Rockefeller University in the laboratory of Hidesaburo Hanafusa, where he received awards from the Howard Hughes Medical Institute and the American Cancer Society. He is currently on the board of directors of Taurus Therapeutics, Umoja Biopharma and Pharvaris.

See also  In the new car market, Latvia lags behind Lithuania and Estonia: Latvia sold the least number of new cars last year

“I am honored to join the Jubilant Therapeutics board of directors and to contribute to the important work the company is doing in the areas of genetically defined cancers and autoimmune diseases,” said Dr. Glassman. “Your portfolio of targeted therapeutics is really differentiated and potentially transformative for patients.”

About Jubilant Therapeutics

Jubilant Therapeutics Inc. is a patient-focused biopharmaceutical company developing potent and selective small molecule modulators to meet medical needs in oncology and autoimmune diseases. Its advanced research strategy integrates structure-based design and computational algorithms to discover and develop novel, precise therapeutics that target both early targets of their kind and validated but persistent targets in genetically defined patient populations. The entrepreneurial management and scientific teams of the company strive for speed and efficiency by applying a business model that leverages the proven and synergetic capabilities of the value chain and joint services of Jubilant Pharmova. Jubilant Therapeutics is headquartered in the United States and is led by globally recognized opinion leaders and members of the Scientific Advisory Board. For more information, please visit www.jubilanttx.com or follow us on Twitter @JubilantTx or LinkedIn.

Logo: https://mma.prnewswire.com/media/1064788/Jubilant_Therapeutics_Logo.jpg


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.